Stephan Glund
About
Stephan Glund is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Molecular Biology.
According to data from OpenAlex, Stephan Glund has authored 41 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cardiology and Cardiovascular Medicine, 12 papers in Surgery and 12 papers in Molecular Biology. Recurrent topics in Stephan Glund's work include Atrial Fibrillation Management and Outcomes (19 papers), Venous Thromboembolism Diagnosis and Management (11 papers) and Adipose Tissue and Metabolism (9 papers). Stephan Glund is often cited by papers focused on Atrial Fibrillation Management and Outcomes (19 papers), Venous Thromboembolism Diagnosis and Management (11 papers) and Adipose Tissue and Metabolism (9 papers). Stephan Glund collaborates with scholars based in Germany, United States and Sweden. Stephan Glund's co-authors include Joachim Stangier, Anna Krook, Juleen R. Zierath, Paul Reilly, Charles V. Pollack, Jeffrey I. Weitz, Joanne van Ryn, Menno V. Huisman, Elaine M. Hylek and Paul A. Reilly and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.
In The Last Decade
Stephan Glund
41 papers receiving 3.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stephan Glund Germany | 23 | 1.6k | 1.1k | 702 | 677 | 531 | 41 | 3.2k | ||
| Umberto Campia United States | 33 | 1.7k 1.1× | 203 0.2× | 545 0.8× | 856 1.3× | 378 0.7× | 86 | 3.6k | ||
| Gian Gastone Neri Serneri Italy | 34 | 1.8k 1.1× | 377 0.3× | 574 0.8× | 437 0.6× | 266 0.5× | 118 | 3.3k | ||
| Marek Postuła Poland | 26 | 881 0.5× | 154 0.1× | 816 1.2× | 212 0.3× | 284 0.5× | 129 | 2.5k | ||
| N. Håkan Wallén Sweden | 27 | 1.0k 0.6× | 272 0.2× | 139 0.2× | 315 0.5× | 192 0.4× | 51 | 2.0k | ||
| Mišo Šabović Slovenia | 25 | 822 0.5× | 181 0.2× | 237 0.3× | 222 0.3× | 306 0.6× | 141 | 2.0k | ||
| Xia Meng China | 22 | 623 0.4× | 166 0.2× | 190 0.3× | 141 0.2× | 1.0k 1.9× | 126 | 2.1k | ||
| Jacek Nowak Sweden | 27 | 1.2k 0.8× | 119 0.1× | 228 0.3× | 392 0.6× | 227 0.4× | 140 | 2.6k | ||
| Masaaki Miyata Japan | 33 | 1.6k 1.0× | 69 0.1× | 603 0.9× | 598 0.9× | 251 0.5× | 134 | 3.4k | ||
| Chi Young Shim South Korea | 36 | 3.4k 2.0× | 98 0.1× | 414 0.6× | 290 0.4× | 919 1.7× | 325 | 5.0k | ||
| Lung‐An Hsu Taiwan | 27 | 689 0.4× | 67 0.1× | 483 0.7× | 295 0.4× | 508 1.0× | 139 | 2.7k |
Countries citing papers authored by Stephan Glund
Since
Specialization
Citations
This map shows the geographic impact of Stephan Glund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Glund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Glund more than expected).
Fields of papers citing papers by Stephan Glund
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Stephan Glund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Glund. The network helps show where Stephan Glund may publish in the future.
Co-authorship network of co-authors of Stephan Glund
This figure shows the co-authorship network connecting the top 25 collaborators of Stephan Glund. A scholar is included among the top collaborators of Stephan Glund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan Glund. Stephan Glund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Glund, Stephan, et al.. (2023). Bioequivalence of Intravenous Alteplase from Two Different Manufacturing Processes in Healthy Male Volunteers: Results from a Two-Stage, Adaptive-Design Study. Clinical Pharmacokinetics. 62(7). 1023–1030.
2.
Lópes, Renato D., James Aisenberg, Paul A. Reilly, et al.. (2019). Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. Circulation. 139(6). 748–756.
3.
Glund, Stephan, et al.. (2019). Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. Journal of Thrombosis and Haemostasis. 17(8). 1319–1328.
4.
Eikelboom, John W., Joanne van Ryn, Paul Reilly, et al.. (2019). Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. Journal of the American College of Cardiology. 74(14). 1760–1768.
5.
Reilly, Paul, Joanne van Ryn, Oliver Grottke, Stephan Glund, & Joachim Stangier. (2016). Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. The American Journal of Emergency Medicine. 34(11). 26–32.
6.
Schmohl, Michael, Stephan Glund, Akiko Harada, et al.. (2016). Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers. Thrombosis and Haemostasis. 117(2). 269–276.
7.
Glund, Stephan, Joachim Stangier, Joanne van Ryn, et al.. (2016). Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study. Clinical Pharmacokinetics. 56(1). 41–54.
8.
Reilly, Paul A., Richard A. Bernstein, Robert Dubiel, et al.. (2015). Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thrombosis and Haemostasis. 114(7). 198–205.
9.
Pollack, Charles V., Paul A. Reilly, John W. Eikelboom, et al.. (2015). Idarucizumab for Dabigatran Reversal. New England Journal of Medicine. 373(6). 511–520.
10.
Moschetti, Viktoria, Stephen H. Norris, Joachim Stangier, et al.. (2015). A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thrombosis and Haemostasis. 113(5). 943–951.
11.
Glund, Stephan, Joachim Stangier, Michael Schmohl, et al.. (2015). Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. The Lancet. 386(9994). 680–690.
12.
Glund, Stephan, Joachim Stangier, Michael Schmohl, et al.. (2014). Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects. Blood. 124(21). 344–344.
13.
Glund, Stephan, Joachim Stangier, Michael Schmohl, et al.. (2013). Abstract 17765: A Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Healthy Male Volunteers. Circulation. 128.
14.
Glund, Stephan, Corinna Schoelch, Leo Thomas, et al.. (2012). Inhibition of acetyl-CoA carboxylase 2 enhances skeletal muscle fatty acid oxidation and improves whole-body glucose homeostasis in db/db mice. Diabetologia. 55(7). 2044–2053.
15.
Deshmukh, Atul S., Yun Chau Long, Thaís de Castro Barbosa, et al.. (2010). Nitric oxide increases cyclic GMP levels, AMP-activated protein kinase (AMPK)α1-specific activity and glucose transport in human skeletal muscle. Diabetologia. 53(6). 1142–1150.
16.
Glund, Stephan & Anna Krook. (2007). Role of interleukin‐6 signalling in glucose and lipid metabolism. Acta Physiologica. 192(1). 37–48.
17.
Long, Yun Chau, Stephan Glund, Pablo M. García-Rovés, et al.. (2006). Opposite Transcriptional Regulation in Skeletal Muscle of AMP-activated Protein Kinase γ3 R225Q Transgenic Versus Knock-out Mice. Journal of Biological Chemistry. 281(11). 7244–7252.
18.
Long, Yun, Stephan Glund, Pablo M. García-Rovés, & Juleen R. Zierath. (2006). Calcineurin Regulates Skeletal Muscle Metabolism via Coordinated Changes in Gene Expression. Journal of Biological Chemistry. 282(3). 1607–1614.
19.
Treebak, Jonas T., Stephan Glund, Atul S. Deshmukh, et al.. (2006). AMPK-Mediated AS160 Phosphorylation in Skeletal Muscle Is Dependent on AMPK Catalytic and Regulatory Subunits. Diabetes. 55(7). 2051–2058.
20.
Stocker, Claire J., Jacqueline O’Dowd, Nicholas M. Morton, et al.. (2003). Modulation of susceptibility to weight gain and insulin resistance in low birthweight rats by treatment of their mothers with leptin during pregnancy and lactation. International Journal of Obesity. 28(1). 129–136.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Umberto Campia Breakdown of academic impact, for papers by Gian Gastone Neri Serneri Breakdown of academic impact, for papers by Marek Postuła Breakdown of academic impact, for papers by N. Håkan Wallén Breakdown of academic impact, for papers by Mišo Šabović Breakdown of academic impact, for papers by Xia Meng Breakdown of academic impact, for papers by Jacek Nowak Breakdown of academic impact, for papers by Masaaki Miyata Breakdown of academic impact, for papers by Chi Young Shim Breakdown of academic impact, for papers by Lung‐An Hsu